Abstract: An energy storage system may include a storage container having an enclosed compartment containing one or more energy storage units and an enclosed compartment duct, an inverter cabinet containing an inverter, the inverter cabinet having one or more inverter cabinet inlets, and an inverter exhaust duct. The storage container may also have a transformer bay containing a transformer. The energy storage system may also include an air temperature control unit, attached to the storage container and configured to circulate conditioned air to the enclosed compartment via the enclosed compartment duct and to the inverter cabinet via the one or more inverter cabinet inlets, and to return air from the enclosed compartment and the inverter cabinet via an air temperature control unit return.

Abstract: In one aspect, a pump-motor assembly is provided outside of and adjacent to a storage container that stores a back-up energy storage unit. The pump-motor assembly includes a pump-motor that maintains a minimum pressure of a liquid coolant in a liquid coolant system that cools the back-up energy storage unit, and a housing that is completely enclosed, the housing containing the pump-motor, and having a removable access panel on one side thereof the enclosed structure, and an opening on another side thereof to the storage container.

Abstract: Disclosed herein are DNA origami nanostmcture that can be functionalized for personalized and targeted drug delivery. The disclosed nanostructures enter cells through the endolysosomal pathway and circumvent drug resistance mechanisms in target cells. The disclosed nanostructures can be loaded small molecule drugs (e.g. anthracyclines, anti-metabolites) and nucleic acids (e.g. antisense oligonucleotides, siRNA, miRNA) with targeting and/or therapeutic antibodies against tumor-specific antigens (e.g. anti-CD33, anti-CD20) that can be modified to treat to a wide range of cancers and ultimately tailored to specific patients' needs for precision medicine.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

Abstract: Disclosed is a highly sensitive mutation-specific quantitative polymerase chain reaction (PCR) assay to detect BTK mutations in B cells.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a BTK inhibitor, e.g., an amino pyrimidine derivative described herein. The invention also provides kits and compositions described herein.

Abstract: The present disclosure relates to the treatment of chronic lymphocytic leukemia. Monoclonal antibody XmAb5574 is efficacious when administered to patient at certain dosage regimens.

Abstract: Biomarkers and methods are disclosed that identify patients being treated with a BTK inhibitor that have acquired a mutation that will cause resistance to the BTK inhibitor. Therefore, also disclosed is a method for treating a hematological cancer in the patient that involves detecting an acquired mutation that causes resistance to a BTK inhibitor and then selecting an alternative treatment if resistance is detected.

Abstract: The present disclosure relates to the treatment of chronic lymphocytic leukemia. Monoclonal antibody XmAb5574 is efficacious when administered to patient at certain dosage regimens. Further disclosed are regimens including said antibody is administered at least once weekly over at least eight weeks; or/and said antibody is administered at a level that achieves a total exposure to said patient measured by area under the curve (AUG) of 14,500 ug*day/ml or more.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

Abstract: The open channel flow meter of the present invention uses a progressive spectral analyzer to increase the efficiency and accuracy thereof. This is accomplished by using a smaller degree fast Fourier transform covering small sections of the span of the sensor. Additional sections of the span are added to the analysis as required to cover the desired velocity range. This approach also allows one to bypass the processing of velocity spans outside the actual site conditions. This allows circuitry which costs less, uses less power, and achieves more precise readings in a shorter time period.

Abstract: A dosing regimen comprising a therapeutically effective amount of flavopiridol or a pharmaceutically acceptable salt thereof optionally in combination with a pharmaceutically acceptable carrier suitable for bolus infusion and subsequently for infusion is disclosed and claimed. Also disclosed and claimed is a method of treating a variety of cancers in a patient comprising administering to said patient the dosing regimen of the invention.

Abstract: A dosing regimen comprising a therapeutically effective amount of flavopiridol or a pharmaceutically acceptable salt thereof optionally in combination with a pharmaceutically acceptable carrier suitable for bolus infusion and subsequently for infusion is disclosed and claimed. Also disclosed and claimed is a method of treating a variety of cancers in a patient comprising administering to said patient the dosing regimen of the invention.

Abstract: Methods and kits are provided for predicting the response of patients with B-cell chronic lymphocytic leukemia (CLL) to treatment with agents that bind to the CD20 and CD 52 antigens on the surface of B lymphocytes. The methods of the present invention are for identifying patients who are refractory and patients who are responsive to therapy with such agents by analyzing the genome of cells obtained from the patients for the presence of specific chromosomal abnormalities, including del(17p13.1), and one or more of del(13q14.3), del(11q22.3) and trisomy 12. The methods are performed using appropriate cytogenetic analysis techniques, such as fluorescence in situ hybridization (FISH), with probes capable of detecting the specific cytogenetic abnormalities. Patients without del(17p13.1) but with del(13q14.3), del(11q22.3) or trisomy for chromosome 12, have been shown to be responsive to agents that bind CD20, such as rituximab. Patients with del(17p13.